BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:AZD4954 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of AZD4954\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07812077-1075@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20270317
DTEND;VALUE=DATE:20270318
SUMMARY:AZD4954: Phase 1 readout est. (NCT07812077)
DESCRIPTION:AZD4954\, phase 1.\nStudy: A Study Designed to Assess the Mass 
 Balance Recovery\, Absorption\, Metabolism\, Excretion of [14C]AZD4954 and
  the Absolute Bioavailability of AZD4954\nEstimated primary completion: 17
  March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/azd4954#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0781
 2077
URL:https://assetmemo.bio/drug/azd4954#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06980428-1075@assetmemo.bio
DTSTAMP:20261121T004047Z
DTSTART;VALUE=DATE:20270409
DTEND;VALUE=DATE:20270410
SUMMARY:AZD4954: Phase 1 readout est. (NCT06980428)
DESCRIPTION:AZD4954\, phase 1\, Atherosclerotic Cardiovascular Disease.\nSt
 udy: A Study to Investigate Safety\, Tolerability\, Pharmacokinetics\, and
  Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without
  Elevated Lipoprotein (a) (Lp[a]) Levels\, and Participants With Dyslipide
 mia\nEstimated primary completion: 9 April 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/azd4954#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06980428
URL:https://assetmemo.bio/drug/azd4954#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
